Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-05 |
2024-09 |
-0.36 |
N/A |
N/A |
N/A |
2024-08-08 |
2024-06 |
-0.34 |
-0.35 |
-0.01 |
-2.94% |
2024-05-09 |
2024-03 |
-0.36 |
-0.34 |
0.02 |
5.56% |
2024-03-27 |
2023-12 |
-0.35 |
-0.33 |
0.02 |
5.71% |
2023-11-07 |
2023-09 |
-0.4 |
-0.39 |
0.01 |
2.50% |
2023-08-10 |
2023-06 |
-0.44 |
-0.32 |
0.12 |
27.27% |
Date |
Firm |
Action |
From |
To |
2023-08-13 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-10 |
B. Riley Securities |
Upgrade |
Buy |
Buy |
2023-07-11 |
JMP Securities |
Upgrade |
Market Outperform |
Market Outperform |
2023-05-14 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-03-30 |
JMP Securities |
Upgrade |
|
Market Outperform |
2023-03-21 |
JMP Securities |
Upgrade |
|
Market Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2024-08-18 |
DRUTZ DAVID J |
Director |
0.00 |
Sale |
2024-01-30 |
EISENSTADT RICHARD I |
Chief Financial Officer |
45.01K |
Stock Award(Grant) |
2024-02-01 |
GARG VIPIN K. |
Chief Executive Officer |
292.03K |
Conversion of Exercise of derivative security |
2022-08-11 |
GILL JOHN M |
Director |
2.77K |
Sale |
2024-07-30 |
HARRIS MATTHEW SCOTT |
Officer |
55.12K |
Stock Award(Grant) |
2024-07-30 |
JORDT RAYMOND M |
Officer |
14.66K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
3.66M |
12.93M |
6.95% |
2023-06-29 |
Nuveen Asset Management, LLC |
3.46M |
12.21M |
6.57% |
2023-06-29 |
Vanguard Group Inc |
3.31M |
11.67M |
6.27% |
2023-06-29 |
Tang Capital Management, LLC |
2.75M |
9.71M |
5.22% |
2023-06-29 |
Marshall Wace LLP |
2.06M |
7.27M |
3.91% |
2023-06-29 |
Laurion Capital Management, LP |
1.84M |
6.49M |
3.49% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
College Retirement Equities Fund-Stock Account |
2.00M |
7.05M |
3.79% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.62M |
5.71M |
3.07% |
2023-06-29 |
College Retirement Equities Fund-Global Equities Account |
1.27M |
4.48M |
2.41% |
2023-08-30 |
iShares Russell 2000 ETF |
1.18M |
3.00M |
2.25% |
2023-06-29 |
Vanguard Extended Market Index Fund |
621.63K |
2.19M |
1.18% |
2023-06-29 |
Vanguard Horizon Fund-Strategic Small-Cap Equity Fund |
490.56K |
1.73M |
0.93% |
Dividend |
Date |
291 |
2017-02-07 |
2.91 |
2017-02-06 |
291.003 |
2017-01-20 |
Split |
Date |
1 : 30 |
2018-09-14 |
10 : 1 |
2017-05-05 |